Developer docs
API playgroundTry for free, no card

Search company profiles

InterCure

Full company profile

uuid0000bvp

Namestring
InterCure
Legal namestring
InterCure Ltd.
Websiteurl
intercure.co
Company typeenum
Public
Founded yearint
2013
Descriptiontext

InterCure Ltd. is a vertically integrated pharmaceutical cannabis company dual-listed on NASDAQ and the Tel Aviv Stock Exchange (ticker: INCR), headquartered in Herzliya, Israel. The company operates a four-pillar platform: Givol, a retail network of 25+ dedicated medical cannabis pharmacies staffed by licensed pharmacists across Israel and Germany; Cannasoul × Technion, an exclusive R&D partnership led by Prof. Dedi Meiri at the Technion conducting 11 active clinical trials and profiling 120+ cannabinoids through the Entourage Effect; Canndoc, the exclusive international distribution platform for 12+ premium cannabis brands (including Cookies, The Flowery, Runtz, DOJA, Backpack Boyz, Preferred Gardens, Wizard Trees) outside North America; and Botanico AI, a proprietary domain-specific intelligence engine processing 2.4M signals per day across 70,000+ patient records with claimed 98% forecast precision over a 12-month planning horizon.

The company's core technology stack is Botanico AI, which automates cultivation planning, predicts pharmacy stockouts before they occur, integrates via live API with Cannasoul's cannabinoid database for product formulation, and surfaces emerging strain preferences from social and purchase data. InterCure distributes 80+ EU-GMP certified SKUs and launched 75+ new GMP products in 2025. The company has invested in vertical integration across genetics (via the June 2026 Botanico acquisition), cultivation, EU-GMP manufacturing, and retail, serving more than 100,000 patients across Israel and Germany.

Revenue is generated through three primary streams: pharmaceutical retail via Givol pharmacies (transaction-fee model), exclusive international brand licensing and distribution of premium U.S. cannabis brands through Canndoc (licensing/royalty and distribution margins), and emerging R&D and AI platform services through the Cannasoul partnership. The company is dual-listed, dual-regulated, and reports 12 consecutive half-years of positive Adjusted EBITDA with FY2025 Adjusted EBITDA of NIS 47M and positive operating cash flow of NIS 17M, a turnaround from -NIS 67M in FY2024. Geographic markets are currently Israel and Germany, with a strategic review of U.S. entry initiated in June 2026.

Short descriptiontext

InterCure is a vertically integrated pharmaceutical cannabis company operating a 25+ Givol pharmacy retail network, exclusive international distribution for premium cannabis brands, Technion-backed cannabinoid R&D, and proprietary Botanico AI, serving 100,000+ patients across Israel and Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHerzliya, Israel
HQ citystring
Herzliya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical cannabis, medical cannabis retail, cannabis brand distribution, EU-GMP cannabis products, cannabis AI platform
Industry3 codes
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAE
Dispensary-Owned Online Ordering & Delivery (Direct-to-Consumer)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Pharmaceutical Cannabis
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Retail (Givol Pharmacies)
TypeTransaction Fee
Description

Revenue from direct-to-patient medical cannabis sales through owned pharmacy network across Israel and Germany. Each Givol pharmacy is staffed by licensed pharmacists and carries the full Canndoc brand portfolio, providing clinical-grade retail experience.

intercure.co
2Brand Licensing and Distribution (Canndoc)
TypeLicensing Royalties
Description

Revenue from exclusive international distribution rights for premium cannabis brands including Cookies, The Flowery, Runtz, Preferred Gardens, Backpack Boyz, and other U.S. operators. The company earns licensing/royalty fees and distribution margins on EU-GMP certified products.

intercure.co
3AI Platform / Technology Services
TypeSubscription Recurring
Description

Botanico AI platform optimizes internal operations across cultivation, supply chain, and retail. While primarily used internally, the platform provides competitive moat enabling operational efficiency and data-driven decision making.

intercure.co
4R&D Partnership Revenue
TypeManaged Services
Description

Strategic partnership with Cannasoul Analytics includes research collaboration, clinical trials, and cannabinoid profiling services. The company holds 28% stake in Cannasoul R&D Ltd. with option to increase to 51%.

globenewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 12 records shown
1Cookies
Description

World's most recognised cannabis brand with exclusive international distribution rights outside North America.

intercure.co
+11 more records
Core offering1 text field

InterCure is a vertically integrated pharmaceutical cannabis company that manufactures and distributes EU-GMP-certified medical cannabis products through its owned Givol pharmacy network (25+ dedicated pharmacies across Israel and Germany) and licenses premium international cannabis brands (Cookies, The Flowery, Runtz) outside North America through its Canndoc distribution platform. The company operates a proprietary Botanico AI platform that automates cultivation planning, supply chain, and patient care across the enterprise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98% forecast precision across global operations
+4 more records
Product overview1 text field

InterCure operates as a vertically integrated pharmaceutical cannabis platform comprising four core pillars: Givol (medical cannabis pharmacy network with 25+ pharmacies in Israel and Germany), Cannasoul × Technion (exclusive R&D partnership for cannabinoid research and clinical trials), Canndoc (global brand portfolio with exclusive international distribution rights for premium brands including Cookies, The Flowery, Runtz, DOJA, and 9 others), and Botanico AI (proprietary intelligence engine for supply chain automation and patient care with 98% forecast precision). The company is dual-listed on NASDAQ and TASE, serving over 100,000 patients across Israel and Germany with 80+ GMP-certified SKUs.

Product and service4 records
1Givol Pharmacy Network
CategoryPharmaceutical Retail
Description

Owned and operated medical cannabis pharmacy network of 25+ dedicated pharmacies across Israel and Germany, staffed by licensed pharmacists, providing clinical-grade patient consultations and dispensing pharmaceutical-grade cannabis products.

2Canndoc Brand Distribution
CategoryBrand Distribution and Licensing
Description

Global brand portfolio and exclusive international distribution platform for premium cannabis brands (Cookies, The Flowery, Runtz, DOJA, and others) outside North America, with 80+ GMP-certified SKUs in active distribution.

3Botanico AI Platform
CategoryAI Technology Platform
Description

Proprietary domain-specific AI platform for pharmaceutical cannabis operations, delivering 98% forecast precision across a 12-month planning horizon. Processes 2.4 million signals daily across 70,000+ patient records, supply chain data, and cannabinoid profiles to automate cultivation planning and real-time pharmacy inventory management.

4Cannasoul × Technion R&D Program
CategoryCannabis Research and Development
Description

Exclusive research partnership with Cannasoul Analytics and Prof. Dedi Meiri's Laboratory of Cancer Biology and Cannabinoid Research at the Technion, conducting 11 active clinical trials and metabolic profiling across 120+ cannabinoids to power product development for the Canndoc brand portfolio.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Strategic partnership and investment agreement with Cannasoul, acquiring 28% stake with option to increase to 51%. Partnership focuses on cannabis research, development, and commercialization. Scientific and regulatory collaborations aim to accelerate cannabis therapeutics development and international expansion. Led by Professor Dedi Meiri of the Technion, mapping the Entourage Effect across 120+ cannabinoids.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive research partnership with Cannasoul Analytics and Prof. Dedi Meiri's Laboratory of Cancer Biology and Cannabinoid Research at the Technion. Partnership includes 11 active clinical trials for chronic pain, PTSD, oncology support, epilepsy, and anxiety/sleep disorders. Prof. Meiri chairs InterCure's Scientific Advisory Board.

3Botanico Ltd. (ISHI)
Strategic tierCoreTypeTechnology or Integration
Description

Acquisition of Botanico Ltd. (also known as ISHI), an Israeli cannabis technology and brand company. Transaction grants access to cannabis genetics, proprietary strains, AI-driven technologies, automated production systems, and brand alliances with U.S. cannabis operators including The Flowery. First tranche completed with 2,471,061 ordinary shares issued.

in.investing.com
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive international distribution rights for Cookies — the world's most recognized cannabis brand — outside North America. Partnership signed in 2020, with Cookies Corners established in Frankfurt and Berlin following Germany's 2024 cannabis legalization. Cookies is the first cannabis company to land on the cover of Forbes.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive partnership through Botanico acquisition providing access to The Flowery's cannabis genetics and brand. The Flowery is Florida's most influential boutique cannabis company, home to brands including 710 Labs, Backpack Boyz, Runtz, Preferred Gardens, and Packwoods through statewide delivery and dispensaries.

6Runtz
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive international distribution partnership for Runtz brand outside North America. Runtz is the Zkittlez × Gelato hybrid that became a cultural phenomenon, born in LA in 2017 and amplified by rapper Yung LB. Crossed over into the Cookies family in 2018.

intercure.co
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tilray Brands
TypeDirect peer
Description

Tilray is a global cannabis leader with operations across Canada, the U.S., Europe (including Germany), and Australia, offering medical cannabis cultivation, distribution, and branded products. Directly comparable to InterCure's vertically integrated pharmaceutical cannabis model spanning Israel and Germany, with overlapping distribution of premium brands and pharmacist-led retail.

TypeDirect peer
Description

Canopy Growth is a Canadian cannabis producer with significant German medical cannabis operations through its EU-GMP facility and Spectrum Therapeutics brand. Comparable to InterCure's pharmaceutical cannabis positioning, EU-GMP certification, and German market expansion strategy.

TypeDirect peer
Description

Aurora is a Canadian licensed producer with established European medical cannabis presence, including German distribution through Aurora Deutschland. Comparable to InterCure's EU-GMP distribution model, medical cannabis focus, and international expansion outside North America.

TypeDirect peer
Description

Cronos Group operates a global cannabis platform with brands including PEACE NATURALS and is owned by Altria. Comparable to InterCure as a publicly listed pharmaceutical-grade cannabis producer pursuing international distribution and brand licensing strategies.

TypeDirect peer
Description

OrganiGram is a Canadian licensed producer focused on medical and recreational cannabis with international ambitions. Comparable to InterCure's pharmaceutical cannabis manufacturing and export model targeting international regulated markets.

TypeBroad incumbent
Description

Curaleaf is a U.S. multi-state cannabis operator with the largest dispensary footprint in the U.S. Comparable to InterCure's Givol pharmacy network as a vertically integrated retail-led cannabis operator, though Curaleaf focuses on U.S. state markets rather than international pharmaceutical distribution.

TypeBroad incumbent
Description

Trulieve is one of the largest U.S. cannabis operators with strong retail presence in Florida and other states. Comparable to InterCure's vertically integrated pharmacy/retail model though concentrated in U.S. medical markets, contrasting with InterCure's international pharmaceutical positioning.

TypeDirect peer
Description

IM Cannabis is an Israeli medical cannabis company with international distribution focus, originally part of the InterCure/Canndoc ecosystem. Direct peer given shared Israeli origins, medical cannabis focus, and international distribution ambitions.

TypeOthers
Description

Cookies is the world's most recognized cannabis brand, of which InterCure holds exclusive international distribution rights outside North America. Compares as a key strategic partner and brand licensor rather than direct competitor, with InterCure serving as Cookies' international gateway.

TypeRegional player
Description

Sanity Group is a German cannabis company with both medical and consumer (post-2024 legalization) operations, including the Vayamed medical brand. Comparable as a Germany-focused cannabis operator competing in the same German medical cannabis market where InterCure has established Cookies Corners.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InterCure

Pharmaceutical Cannabisintercure.co

InterCure is a vertically integrated pharmaceutical cannabis company operating a 25+ Givol pharmacy retail network, exclusive international distribution for premium cannabis brands, Technion-backed cannabinoid R&D, and proprietary Botanico AI, serving 100,000+ patients across Israel and Germany.

What InterCure does

InterCure Ltd. is a vertically integrated pharmaceutical cannabis company dual-listed on NASDAQ and the Tel Aviv Stock Exchange (ticker: INCR), headquartered in Herzliya, Israel. The company operates a four-pillar platform: Givol, a retail network of 25+ dedicated medical cannabis pharmacies staffed by licensed pharmacists across Israel and Germany; Cannasoul × Technion, an exclusive R&D partnership led by Prof. Dedi Meiri at the Technion conducting 11 active clinical trials and profiling 120+ cannabinoids through the Entourage Effect; Canndoc, the exclusive international distribution platform for 12+ premium cannabis brands (including Cookies, The Flowery, Runtz, DOJA, Backpack Boyz, Preferred Gardens, Wizard Trees) outside North America; and Botanico AI, a proprietary domain-specific intelligence engine processing 2.4M signals per day across 70,000+ patient records with claimed 98% forecast precision over a 12-month planning horizon.

The company's core technology stack is Botanico AI, which automates cultivation planning, predicts pharmacy stockouts before they occur, integrates via live API with Cannasoul's cannabinoid database for product formulation, and surfaces emerging strain preferences from social and purchase data. InterCure distributes 80+ EU-GMP certified SKUs and launched 75+ new GMP products in 2025. The company has invested in vertical integration across genetics (via the June 2026 Botanico acquisition), cultivation, EU-GMP manufacturing, and retail, serving more than 100,000 patients across Israel and Germany.

Revenue is generated through three primary streams: pharmaceutical retail via Givol pharmacies (transaction-fee model), exclusive international brand licensing and distribution of premium U.S. cannabis brands through Canndoc (licensing/royalty and distribution margins), and emerging R&D and AI platform services through the Cannasoul partnership. The company is dual-listed, dual-regulated, and reports 12 consecutive half-years of positive Adjusted EBITDA with FY2025 Adjusted EBITDA of NIS 47M and positive operating cash flow of NIS 17M, a turnaround from -NIS 67M in FY2024. Geographic markets are currently Israel and Germany, with a strategic review of U.S. entry initiated in June 2026.

InterCure firmographics

Firmographics
Name
InterCure
Legal name
InterCure Ltd.
Website
https://intercure.co
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
InterCure is a vertically integrated pharmaceutical cannabis company operating a 25+ Givol pharmacy retail network, exclusive international distribution for premium cannabis brands, Technion-backed cannabinoid R&D, and proprietary Botanico AI, serving 100,000+ patients across Israel and Germany.
Ownership category
akta.pro rank

InterCure industry classification

Industry
Product category
Pharmaceutical Cannabis
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAE
Dispensary-Owned Online Ordering & Delivery (Direct-to-Consumer)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail

Keywords

  • Pharmaceutical cannabis
  • Medical cannabis retail
  • Cannabis brand distribution
  • EU-GMP cannabis products
  • Cannabis AI platform

Where InterCure is headquartered

Location

Headquarters

HQ city
Herzliya
HQ country
Israel
HQ region
Middle East

Offices4 records

Markets served

InterCure business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Retail (Givol Pharmacies): Revenue from direct-to-patient medical cannabis sales through owned pharmacy network across Israel and Germany. Each Givol pharmacy is staffed by licensed pharmacists and carries the full Canndoc brand portfolio, providing clinical-grade retail experience.
  2. Brand Licensing and Distribution (Canndoc): Revenue from exclusive international distribution rights for premium cannabis brands including Cookies, The Flowery, Runtz, Preferred Gardens, Backpack Boyz, and other U.S. operators. The company earns licensing/royalty fees and distribution margins on EU-GMP certified products.
  3. AI Platform / Technology Services: Botanico AI platform optimizes internal operations across cultivation, supply chain, and retail. While primarily used internally, the platform provides competitive moat enabling operational efficiency and data-driven decision making.
  4. R&D Partnership Revenue: Strategic partnership with Cannasoul Analytics includes research collaboration, clinical trials, and cannabinoid profiling services. The company holds 28% stake in Cannasoul R&D Ltd. with option to increase to 51%.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

InterCure product offering

Product offering

Core offering

InterCure is a vertically integrated pharmaceutical cannabis company that manufactures and distributes EU-GMP-certified medical cannabis products through its owned Givol pharmacy network (25+ dedicated pharmacies across Israel and Germany) and licenses premium international cannabis brands (Cookies, The Flowery, Runtz) outside North America through its Canndoc distribution platform. The company operates a proprietary Botanico AI platform that automates cultivation planning, supply chain, and patient care across the enterprise.

Product overview

InterCure operates as a vertically integrated pharmaceutical cannabis platform comprising four core pillars: Givol (medical cannabis pharmacy network with 25+ pharmacies in Israel and Germany), Cannasoul × Technion (exclusive R&D partnership for cannabinoid research and clinical trials), Canndoc (global brand portfolio with exclusive international distribution rights for premium brands including Cookies, The Flowery, Runtz, DOJA, and 9 others), and Botanico AI (proprietary intelligence engine for supply chain automation and patient care with 98% forecast precision). The company is dual-listed on NASDAQ and TASE, serving over 100,000 patients across Israel and Germany with 80+ GMP-certified SKUs.

Differentiator

Problem solved

Functional benefit

Brands

  • Cookies: World's most recognised cannabis brand with exclusive international distribution rights outside North America.
  • The Flowery
  • DOJA
  • Runtz
  • Backpack Boyz
  • Kootenay Quantum
  • Packs
  • Preferred Gardens
  • Totem
  • Purple Farm
  • Koots Canna
  • Wizard Trees

Products and services

  • Givol Pharmacy Network Owned and operated medical cannabis pharmacy network of 25+ dedicated pharmacies across Israel and Germany, staffed by licensed pharmacists, providing clinical-grade patient consultations and dispensing pharmaceutical-grade cannabis products.
  • Canndoc Brand Distribution Global brand portfolio and exclusive international distribution platform for premium cannabis brands (Cookies, The Flowery, Runtz, DOJA, and others) outside North America, with 80+ GMP-certified SKUs in active distribution.
  • Botanico AI Platform Proprietary domain-specific AI platform for pharmaceutical cannabis operations, delivering 98% forecast precision across a 12-month planning horizon. Processes 2.4 million signals daily across 70,000+ patient records, supply chain data, and cannabinoid profiles to automate cultivation planning and real-time pharmacy inventory management.
  • Cannasoul × Technion R&D Program Exclusive research partnership with Cannasoul Analytics and Prof. Dedi Meiri's Laboratory of Cancer Biology and Cannabinoid Research at the Technion, conducting 11 active clinical trials and metabolic profiling across 120+ cannabinoids to power product development for the Canndoc brand portfolio.

Quantifiable outcome

  • 98% forecast precision across global operations
  • +4 more outcomes

Companies that use InterCure

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

InterCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

InterCure partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • Cannasoul R&D Ltd.coreStrategic or Co-development Partner · 3 November 2025Strategic partnership and investment agreement with Cannasoul, acquiring 28% stake with option to increase to 51%. Partnership focuses on cannabis research, development, and commercialization. Scientific and regulatory collaborations aim to accelerate cannabis therapeutics development and international expansion. Led by Professor Dedi Meiri of the Technion, mapping the Entourage Effect across 120+ cannabinoids.
  • Technion (Israel Institute of Technology)coreStrategic or Co-development PartnerExclusive research partnership with Cannasoul Analytics and Prof. Dedi Meiri's Laboratory of Cancer Biology and Cannabinoid Research at the Technion. Partnership includes 11 active clinical trials for chronic pain, PTSD, oncology support, epilepsy, and anxiety/sleep disorders. Prof. Meiri chairs InterCure's Scientific Advisory Board.
  • Botanico Ltd. (ISHI)coreTechnology or IntegrationAcquisition of Botanico Ltd. (also known as ISHI), an Israeli cannabis technology and brand company. Transaction grants access to cannabis genetics, proprietary strains, AI-driven technologies, automated production systems, and brand alliances with U.S. cannabis operators including The Flowery. First tranche completed with 2,471,061 ordinary shares issued.
  • CookiesflagshipChannel Partner/ Reseller/ DistributorExclusive international distribution rights for Cookies — the world's most recognized cannabis brand — outside North America. Partnership signed in 2020, with Cookies Corners established in Frankfurt and Berlin following Germany's 2024 cannabis legalization. Cookies is the first cannabis company to land on the cover of Forbes.
  • The FlowerycoreChannel Partner/ Reseller/ DistributorExclusive partnership through Botanico acquisition providing access to The Flowery's cannabis genetics and brand. The Flowery is Florida's most influential boutique cannabis company, home to brands including 710 Labs, Backpack Boyz, Runtz, Preferred Gardens, and Packwoods through statewide delivery and dispensaries.
  • RuntzcoreChannel Partner/ Reseller/ DistributorExclusive international distribution partnership for Runtz brand outside North America. Runtz is the Zkittlez × Gelato hybrid that became a cultural phenomenon, born in LA in 2017 and amplified by rapper Yung LB. Crossed over into the Cookies family in 2018.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

InterCure competitors and assessment

Company assessment

Direct peers

  • Tilray Brands: Tilray is a global cannabis leader with operations across Canada, the U.S., Europe (including Germany), and Australia, offering medical cannabis cultivation, distribution, and branded products. Directly comparable to InterCure's vertically integrated pharmaceutical cannabis model spanning Israel and Germany, with overlapping distribution of premium brands and pharmacist-led retail.
  • Canopy Growth Corporation: Canopy Growth is a Canadian cannabis producer with significant German medical cannabis operations through its EU-GMP facility and Spectrum Therapeutics brand. Comparable to InterCure's pharmaceutical cannabis positioning, EU-GMP certification, and German market expansion strategy.
  • Aurora Cannabis: Aurora is a Canadian licensed producer with established European medical cannabis presence, including German distribution through Aurora Deutschland. Comparable to InterCure's EU-GMP distribution model, medical cannabis focus, and international expansion outside North America.
  • Cronos Group: Cronos Group operates a global cannabis platform with brands including PEACE NATURALS and is owned by Altria. Comparable to InterCure as a publicly listed pharmaceutical-grade cannabis producer pursuing international distribution and brand licensing strategies.
  • OrganiGram Holdings: OrganiGram is a Canadian licensed producer focused on medical and recreational cannabis with international ambitions. Comparable to InterCure's pharmaceutical cannabis manufacturing and export model targeting international regulated markets.
  • IM Cannabis (formerly InterCure subsidiary, now separate): IM Cannabis is an Israeli medical cannabis company with international distribution focus, originally part of the InterCure/Canndoc ecosystem. Direct peer given shared Israeli origins, medical cannabis focus, and international distribution ambitions.

Broad incumbents

  • Curaleaf Holdings: Curaleaf is a U.S. multi-state cannabis operator with the largest dispensary footprint in the U.S. Comparable to InterCure's Givol pharmacy network as a vertically integrated retail-led cannabis operator, though Curaleaf focuses on U.S. state markets rather than international pharmaceutical distribution.
  • Trulieve Cannabis: Trulieve is one of the largest U.S. cannabis operators with strong retail presence in Florida and other states. Comparable to InterCure's vertically integrated pharmacy/retail model though concentrated in U.S. medical markets, contrasting with InterCure's international pharmaceutical positioning.

Others

  • Cookies (cannabis brand): Cookies is the world's most recognized cannabis brand, of which InterCure holds exclusive international distribution rights outside North America. Compares as a key strategic partner and brand licensor rather than direct competitor, with InterCure serving as Cookies' international gateway.

Regional players

  • Sanity Group: Sanity Group is a German cannabis company with both medical and consumer (post-2024 legalization) operations, including the Vayamed medical brand. Comparable as a Germany-focused cannabis operator competing in the same German medical cannabis market where InterCure has established Cookies Corners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

InterCure social profiles

Digital presence

InterCure compliance and trust

Trust signal

Compliance1 record

InterCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InterCure leadership team

Management profile

Number of profiles

Profiles8 records

InterCure subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

InterCure funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InterCure M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InterCure

What does InterCure do?

InterCure is a vertically integrated pharmaceutical cannabis company that manufactures and distributes EU-GMP-certified medical cannabis products through its owned Givol pharmacy network (25+ dedicated pharmacies across Israel and Germany) and licenses premium international cannabis brands (Cookies, The Flowery, Runtz) outside North America through its Canndoc distribution platform. The company operates a proprietary Botanico AI platform that automates cultivation planning, supply chain, and patient care across the enterprise.

Is InterCure a public or private company?

InterCure is a public company. It is classified as public and is currently operating.

When was InterCure founded?

InterCure was founded in 2013. It employs 11 to 50 people.

Where is InterCure based?

InterCure is headquartered in Herzliya, Israel, in the Middle East region.

How does InterCure make money?

Four revenue lines are on record. Pharmaceutical Retail (Givol Pharmacies) is the primary driver. The others are brand Licensing and Distribution (Canndoc), AI Platform / Technology Services and R&D Partnership Revenue.

Who are InterCure's main competitors?

Direct peers on record are Tilray Brands, Canopy Growth Corporation, Aurora Cannabis, Cronos Group, OrganiGram Holdings and IM Cannabis (formerly InterCure subsidiary, now separate). Broad incumbents are Curaleaf Holdings and Trulieve Cannabis. Cookies (cannabis brand) is listed as an others. Sanity Group is listed as a regional player.

Does InterCure have an API?

No public API is recorded for InterCure.

What industry is InterCure in?

InterCure's product category is Pharmaceutical Cannabis. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail). Its NAICS code is 325411 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsOno Pharmaceutical (OTCMKTS:OPHLF) vs. InterCure (NASDAQ:INCR) Financial ComparisonOno Pharmaceutical beats InterCure on 7 of 9 financial factors, including higher revenue ($3.43B vs $78.47M) and earnings ($436M vs -$10.37M). Ono's beta of 0.38 indicates lower volatility than InterCure's 1.43, and its analyst rating score is 2.00 versus 1.00.Defense WorldComparing Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR)Tilray Brands beats InterCure on 8 of 15 factors, including higher revenue and earnings. Tilray trades at a lower P/E ratio and has a stronger analyst consensus with a $7.00 target price, implying 77.22% upside.Markets DailyTilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR) Critical ComparisonTilray Brands and InterCure are compared on profitability, analyst ratings, and valuation. Tilray beats InterCure on 9 of 15 factors, with a consensus target price of $7.00 implying 69.49% upside. Tilray is also more affordable, trading at a lower price-to-earnings ratio.Markets DailyContrasting Silo Pharma (NASDAQ:SILO) and InterCure (NASDAQ:INCR)InterCure and Silo Pharma are compared on valuation, earnings, and analyst ratings. InterCure beats Silo Pharma on 8 of 11 factors, including institutional ownership and volatility. Silo Pharma trades at a lower price-to-earnings ratio but has lower revenue.MarketScreenerInterCure Regains Nasdaq ComplianceInterCure Ltd., an Israel-based medical cannabis company, regained Nasdaq compliance. The company cultivates, produces, and distributes pharmaceutical-grade medical cannabis products under its subsidiary Canndoc Ltd., operating across cultivation, manufacturing, logistics, and retail. It also imports and exports medical cannabis products in Israel and selected international markets.YahooInterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?InterCure Ltd. finalized a NIS 230 million, or about $77 million, settlement with Israeli authorities covering indirect damages from the October 7, 2023 attacks and the subsequent war. About $34 million had already been advanced, leaving roughly $43 million of implied remaining gross compensation, roughly 2.6 times the company's NIS 49 million cash on hand. Payment timing and net cash receipt were not disclosed.Insider Trading & Hedge Fund DataInterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?InterCure Ltd. finalized a NIS 230 million, or about $77 million, settlement with Israeli authorities for indirect damages from the October 7, 2023 attacks, having already received NIS 101 million, or roughly $34 million, in advances. The remaining implied gross compensation is about NIS 129 million, or $43 million, roughly 2.6 times the company's NIS 49 million cash on hand. Payment timing and rehabilitation costs were not disclosed.NasdaqInterCure Secures NIS 230 Million Settlement; Reverse Stock Split Effective Today; Stock UpInterCure Ltd. announced it has finalized a settlement with the Israeli Tax Authorities and Compensation Fund for indirect damages from the October 7, 2023 attacks, totaling NIS 230 million (about US$77 million). The company had previously claimed over NIS 300 million and received NIS 101 million in advance payments. The funds will accelerate rehabilitation of its damaged Kibbutz Nir Oz facility.Investing.comInterCure settles tax claim for $77M after October 7 attack By Investing.comInterCure Ltd. has reached a final settlement with Israeli Tax Authorities for NIS 230 million (approximately $77 million) to compensate for indirect damages resulting from the October 7, 2023 attacks. The settlement resolves a claim originally exceeding NIS 300 million, following severe damage to Canndoc's production facility at Kibbutz Nir Oz which impacted the company's operations. InterCure plans to use these resources to accelerate the rehabilitation of the facility and support its expansion into the German medical cannabis market.Stock TitanInterCure Finalizes NIS 230M War-Damage SettlementInterCure Ltd. finalized a settlement with the Israeli Tax Authorities and Compensation Fund to receive NIS 230 million in compensation for indirect damages caused by the October 7, 2023 attacks. The company intends to use these funds to accelerate the rehabilitation of its flagship Nir Oz facility and support expansion into the German medical cannabis market.